Eversept Partners’s Cellectis CLLS Stock Holding History

Eversept Partners’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-30,000	Closed	-$849K	–	67
2018 Q2	$849K	Buy	+30,000	New	+$893K	0.39%	46

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Eversept Partners's CLLS Position: Q3 2018 in Review

Eversept Partners sold out of Cellectis (CLLS) in Q3 2018, closing a stake of 30,000 shares — an estimated $849K sold.

Eversept Partners first reported a position in CLLS in Q2 2018 and held it in 1 quarter. The position peaked at $849K in Q2 2018. 81 funds tracked by Wall St. Rank hold CLLS as of Q3 2018.

Eversept Partners reported no remaining Cellectis position as of Q3 2018 after selling out during the quarter.
Eversept Partners sold 30,000 Cellectis shares in Q3 2018, an estimated $849K.
Eversept Partners first reported a position in Cellectis in Q2 2018 and held it in 1 quarter.
Eversept Partners's Cellectis position peaked at $849K in Q2 2018.
81 funds tracked by Wall St. Rank held Cellectis as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.